Fennec Pharmaceuticals (FENC) Stock Forecast & Price Target

Fennec Pharmaceuticals is viewed favorably because PEDMARK is gaining traction across new and existing accounts, with 2Q26 net product sales of $17.2M, total revenue of $17.9M, and seven consecutive quarters of growth reflecting expanding utilization and a broader prescriber base. The company is also showing improving fundamentals, including first-time non-GAAP adjusted EBITDA of $2.8M, operating income of $1.7M, flat cash OpEx near $13.6M, and cash and equivalents of $41.2M, which together suggest rising operating leverage and better financial resilience. Longer-term upside is supported by potential NCCN reclassification by early 2028, possible Japan entry in 2027, and extended exclusivity to at least September 1, 2033, all of which could materially expand demand and profitability.

Fennec Pharmaceuticals is a highly concentrated single-asset story, with 100% of revenue tied to PEDMARK and no internal pipeline, so any shortfall in commercial execution or clinical expansion must be funded externally and could create dilution risk. Patent litigation is a major overhang because unfavorable outcomes could compress the exclusivity runway to the ODE floor, while reimbursement remains fragile as AYA use depends on off-label NCCN Category 2A support and pediatric uptake faces DRG-bundled economics that favor compounded STS at 70-90% discounts. With cash of $42M as of December 2025 and an expanding commercial cost base, the company appears financially exposed if account activation, formulary access, and revenue acceleration fail to meet expectations.